Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Other rare side-effects, such as hepatic impairment and interstitial lung disease, should be identified early and managed carefully. Patients with uncommon EGFR mutations, such as G719X, S768I, and L861Q, may require special selection of EGFR TKIs. The combination of erlotinib plus bevacizumab has been accepted in certain parts of the world as an alternative front-line treatment. This review article summarizes the studies leading to the establishment of EGFR TKIs in EGFR-mutant lung cancer patients. The side-effect profiles of the current EGFR TKIs in these large trials are listed, and the management of uncommon EGFR mutations is discussed. Finally, the potential role of combination front-line treatment is discussed.
Introduction
Patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation are a special group of individuals. The aetiology of the cancer, the clinicopathological features, the prognosis and treatment paradigms are all different when compared with other NSCLC patients [1] . EGFR mutations in NSCLC cells were first discovered in 2004 [2, 3] . The majority of EGFR mutations in NSCLC occurs in exons 18-21 of the tyrosine kinase domain of the receptor. EGFR mutations occur in 40%-60% of South-East Asian patients or 10%-20% of Caucasian patients with lung adenocarcinomas [4] [5] [6] . Most EGFR mutation positive tumours are in patients who were never smokers or light smokers, but the observation is not exclusive. Due to an increasing prevalence of non-smoking behaviour, more female patients have EGFR mutations than male patients. In the Iressa Pan Asian Survival Study (IPASS) trial that accrued Asian non-or never smoking lung adenocarcinoma patients, 80% of the subjects were female, and in this trial 60% of the tumours harboured EGFR mutations [7] .
EGFR mutations occur in several hotspots between exons 18 and 21. In-frame deletion of exon 19 and L858R point mutation in exon 21 are the most common types of mutations detected, and account for 50% and 40% of patients' samples, respectively [8] . Both types of mutations are sensitising mutations and tumours harbouring these mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs).
Other EGFR mutations, including G718X, S768I, L861Q, etc., are less common. A special type of EGFR mutation-in-frame insertion in exon 20-occurs in 3%-7% of NSCLC. Most tumours with this type of mutation are resistant to treatment with EGFR TKIs [9] . Reports on this treatment were mostly retrospective and with a limited number of patients and the overall evidence on the use of first-generation TKIs in this group of patients is poor. Yang et al., however, reported the efficacy of afatinib in these uncommon mutations [10] .
First-generation EGFR TKIs
Gefitinib and erlotinib are reversible EGFR TKIs. Both drugs are quinazoline-based derivatives and act as ATP competitive inhibitors that bind to the tyrosine kinase pocket of EGFR [11] . Both drugs exhibit high inhibitory activity against wild-type EGFR and sensitive mutant EGFR.
Several phase II studies have suggested that these two drugs are very active against tumours with EGFR mutations [5, [12] [13] [14] [15] . On the other hand, the activity of gefitinib and erlotinib in patients with EGFR wild-type (EGFRwt) NSCLC is limited. In a metaanalysis that included 1605 patients with EGFRwt in 11 trials, EGFR TKIs were associated with shorter progression-free survival (PFS) compared with cytotoxic chemotherapy (HR: 1.41; 95% CI: 1.10-1.81). A lower objective response rate (RR) was also noted with TKIs compared with chemotherapy (7.2% versus 16.8%, respectively). However, no significant difference of overall survival (OS) was found (HR for TKI: 1.08; 95% CI: 0.96-1.22) [16] .
The large randomised phase III IPASS study used clinical selection to enrich for tumours harbouring EGFR mutations. A total of 1267 Asian untreated stage IIIB/IV NSCLC patients, who were all either light or never smokers, were randomised to gefitinib or carboplatin and paclitaxel [6] . The primary end point of this study (PFS) was superior with gefitinib treatment (HR for TKI: 0.74; 95% CI: 0.65-0.85). In the pre-planned biomarker analysis, gefitinib was superior to chemotherapy in patients with tumours that harboured an activating EGFR mutation: PFS HR: 0.48; 95% CI: 0.36-0.64; P < 0.001); RR 71.2% with gefitinib versus 47.3% with chemotherapy, respectively. On the other hand, gefitinib was inferior to chemotherapy in other subgroups. This study established gefitinib as first-line treatment of patients with tumours harbouring EGFR mutations, and established EGFR mutation status as the best biomarker for EGFR TKI treatment.
In total, six large phase III studies have randomised patients with EGFR mutation positive tumours to EGFR TKIs (gefitinib or erlotinib) or chemotherapy [6, [17] [18] [19] [20] [21] (Table 1 ). All studies showed that EGFR TKIs were better than chemotherapy in terms of RR and PFS. However, no statistically significant improvement in OS was demonstrated, probably due to the high cross-over rate between the EGFR TKI and chemotherapy arms in these six studies [22] .
Second-generation EGFR TKIs
Afatinib and dacomitinib are irreversible EGFR TKIs. Their structures are similar to gefitinib or erlotinib with a quinazoline backbone [23, 24] . However, a side chain was designed to covalently bind to the C797 site of EGFR, thus creating an irreversible inhibition of the EGFR tyrosine kinase. Afatinib and dacomitinib demonstrated in vitro activity against activating EGFR mutations as well as wild-type EGFR. At higher concentrations, these TKIs also demonstrated activity against the exon 20 T790M mutation, the presence of which has been described as the most common cause of secondary resistance to first-generation EGFR TKIs [25] . Both drugs were studied in unselected patients who have progressed on either gefitinib or erlotinib, and specifically in patients harbouring tumours with documented exon 20 T790M mutations in large randomised phase III trials [26, 27] . However, both drugs showed no significant clinical activity in these cohorts of patients.
Afatinib was tested as first-line treatment against chemotherapy in patients with EGFR-mutant tumours in two large randomised phase III trials [10, 28] . Both studies showed higher RR, PFS, and relief of cancer-related symptoms compared with chemotherapy [28, 29] (Table 2 ). In these LUX-Lung 3 and LUXLung 6 trials, patients with EGFR deletion 19 mutations treated with afatinib survived longer than patients who started with chemotherapy [10, 28, 29] .
EGFR TKIs were compared head-to-head in several randomised phase III studies. In an unselected advanced stage NSCLC cohort, erlotinib was not different from gefitinib as second line therapy in a Japanese population with EGFR mutations [30] .
Two studies compared second-to first-generation EGFR TKIs in an EGFR-mutant population. The LUX-Lung 7 trial randomised patients to afatinib or gefitinib [31] . At the time of reporting, with a median follow-up of 27.3 months (IQR: 15.3-33.9), patients in the afatinib arm demonstrated a higher RR (70% versus 56%, respectively), and a statistically significant difference in PFS [median 11.0 months (95% CI: 10.6-12.9) versus 10.9 months (9.1-11.5); HR: 0.73 (95% CI: 0.57-0.95), P ¼ 0.017]. Time-to-treatment failure was also significantly longer with afatinib compared with gefitinib [median 13.7 months (95% CI: 11.9-15.0) versus 11.5 months (10.1-13.1); HR: 0.73 (95% CI: 0.58-0.92), P ¼ 0.0073]. However, after a medium follow-up of 42.6 months, there was no difference in OS with afatinib versus gefitinib (median 27.9 versus 24.5 months, HR: 0.86; 95% CI: 0.66-1.12, P ¼ 0.2580). No significant difference was found in pre-specified del 19 or L858R mutation subgroups [32] .
More recently, the ARCHER study, with 452 patients with EGFR-mutant tumours who were randomised to dacomitinib or gefitinib as first-line treatment, has been reported [33] . Although the RR were similar in both arms (75% in dacomitinib-versus 72% gefitinib-treatment arms; P ¼ 0.39), the PFS of the dacomintinib arm was statistically prolonged compared with gefitinib arm (14.7 versus 9.2 months by independent review, HR: 0.59; 95% CI: 0.47-0.74). The OS data had not reached maturity at the time of reporting, and these results are eagerly awaited.
Side-effects
Owing to the irreversible binding activity and high potency EGFRwt inhibition of second-generation EGFR TKIs, afatinib, at the recommended dose of 40 mg daily, and dacomitinib, at 45 mg daily, have both been shown to be associated with a higher incidence and severity of adverse events (AEs) when compared with the recommended doses of first-generation EGFR TKIs. The grade 3 and 4 AE rate, grade 5 AE rate, and drug discontinuation rates are summarised in Tables 1 and 2 .
Dose reduction is a common method employed within the landmark trials as well as daily clinical practice to mitigate sideeffects which would otherwise make the treatment intolerable. The antitumour activity and side-effect improvement after dose reduction of afatinib in the LUX-Lung-3 trial were carefully collected. These findings were correlated with the plasma afatinib [34] .
The most common side-effects of EGFR TKIs such as diarrhoea, acneiform skin rash, and paronychia. Other less common side-effects, but of significant clinical importance, such as mucositis, stomatitis, cornea erosion, and epistaxis. The prevalence and severity of these side-effects are associated with the potency of EGFR inhibition. Interstitial lung disease (ILD), and liver function abnormalities have been considered idiosyncratic in nature and are typically not correlated with the strength of EGFR inhibition. ILD often leads to discontinuation of EGFR TKI treatment in patients. Severe hepatic impairment can be resolved after switching to another EGFR TKI [35] , whereas other side-effects that are associated with EGFR inhibition potency can be managed with temporary dose interruption and further dose reduction. Of note, the incidence of liver toxicity in gefitinib seems to be higher in Asian patients versus non-Asian patients [36] . In a reported series, re-challenging with lower dose intensity of gefitinib has not resulted in inferior survival [37] .
Special populations Brain or leptomeningeal metastasis
Patients with EGFR-mutant tumours frequently develop brain metastasis. The activity of EGFR TKIs in brain metastasis was initially described in multiple case series. In the LUX-Lung-3 trial, patients who had brain metastasis were not excluded from participation. While, in general, the presence of brain metastases was a negative prognostic factor, patients who had asymptomatic brain metastasis in the LUX-Lung-3 trial also had better PFS with afatinib compared with chemotherapy [38] .
In a retrospective study analysing patients with EGFR mutation positive tumours who had presented with brain metastasis at first diagnosis, patients who received stereotactic radiosurgery followed by an EGFR TKI had longer OS than those who received whole brain radiotherapy. This study suggested that deferral of radiotherapy in preference of EGFR TKI treatment would be associated with inferior OS [39] . While some adjustment for prognostic factors was made in this study, its retrospective nature warrants further investigations in a prospective manner. Specifically, an important group of patients were missing from this study: those with an EGFR mutation positive tumour with brain metastases who received EGFR TKI alone and who did not ever require subsequent cranial irradiation. This subset of patients is likely to be the individuals who will benefit the most from EGFR TKI for their brain metastases [40] . Therefore, it remains unclear whether upfront radiotherapy is needed for patients with EGFR-mutant tumours and asymptomatic brain metastasis.
Leptomeningeal metastasis (LM) is a serious condition for all solid cancers. Most patients do not respond to conventional treatment and patients with LM have disease of a rapid tempo which inevitably leads to further disease progression and eventual demise. A recently published series reported that NSCLC patients with tumours harbouring EGFR mutations who received EGFR TKI lived longer than those without treatment, suggesting that EGFR TKIs are useful for the control of LM in this patient population [41] . Here, we may expect better outcomes from third-generation EGFR TKIs.
Elderly patients and patients with poor performance patients
In most prospective studies, patients with older age and/or poor performance status were excluded. Admittedly, poor performance status was a poor prognostic and negative predictive factor for EGFR TKI treatment in patients with EGFR mutation positive tumours. Despite these odds, in a Japanese prospective study, patients who had a performance status of 3 or 4 still benefited from gefitinib treatment [12] . The RR was 66% and median OS was 17.8 months. Age was analysed as a predictive factor in several large phase III randomised trials that included an EGFR TKI as one of the experimental arms of treatment. The consensus is that age alone should not be regarded as a predictive factor for EGFR TKI efficacy [42] .
EGFR mutation types Common EGFR mutations
Tumours with EGFR exon 19 deletion mutation seem to respond better to EGFR TKIs compared with those with exon 21 L858R point mutation. In the meta-analysis summarising studies comparing EGFR TKIs to chemotherapy, the HR of PFS of EGFR TKI versus chemotherapy was 0.24 (95% CI: 0.20-0.29) for tumours with exon 19 deletion and 0.48 (95% CI: 0.39-0.58) in those with exon 21 L858R point mutation (P interaction <0.001) [42] . However, the median PFS of chemotherapy in patients with exon 21 L858R point mutations was 1 month longer than those with exon 19 deletion. In the fusion of the results of the LUX-Lung-3 and 6 studies, an OS difference was noted in patients with tumours with exon 19 deletion, not in those with exon 21 L858R point mutation [10] , although there is no significant difference in OS between exons 19 and 21 in the LUX-Lung 7 study. All of these findings suggest that there may be fundamental biological differences and/or responsiveness to treatment between these two types of activating EGFR mutations.
Occasionally, tumours have an activating EGFR mutation in conjunction with the exon 20 T790M resistance mutation at the time of diagnosis. The incidence of the double mutations has varied among studies as there are discrepancies in the sensitivity and specificity of the techniques used to detect T790M in patients' samples. With less sensitive methods, such as Sanger's Direct Sequencing or Scorpion ARMS (Therascreen), the presence of T790M predicted for low sensitivity against EGFR TKIs, including the second-generation EGFR TKI afatinib. These patients should probably be treated with a third-generation mutant-specific EGFR TKI such as osimertinib. However, with highly sensitive methods, such as DNA mass array, the presence of T790M does not preclude the patients from using first-or second-generation EGFR TKIs as front-line treatment [43] . Su et al. reported that more T790M coexistence with EGFR activating mutations was found in TKI-naïve patients by DNA mass array than by direct sequencing (25.2% versus 2.8%, P < 0.001). Co-occurrence of T790M with an exon 19 or exon 21 L858R point was an independent predictor of decreased PFS in patients with NSCLC who received TKI treatment, compared with those without T790M mutation (P < 0.05 by multivariate Cox regression).
Uncommon EGFR mutations
Ten to fifteen per cent of patients with tumours harbouring EGFR mutations present with uncommon EGFR mutations, defined as EGFR mutations which are neither exon 19 deletion of exon 21 L858R point mutation. The efficacy of EGFR TKIs in these uncommon EGFR mutations is less well understood. A pooled analysis of afatinib front-line studies showed that patients with exon 20 insertion mutation responded poorly to afatinib, whereas patients with G719X, S768I, and L861Q responded well to afatinib, with a PFS comparable to common EGFR mutations [10, 44] . A large retrospective study from Taiwan collected treatment results in uncommon EGFR mutations, and showed that patients with G718X and L861Q had shorter PFS with gefitinib or erlotinib [45] .
EGFR TKI combinations
EGFR TKIs were combined with many targeted therapies and chemotherapy as front-line treatment in EGFR mutation positive patients. A meta-analysis of the subgroups of patients with EGFRmutant tumours in the INTACT1, INTACT2, TRIBUTE, and TALENT studies showed that gefitinib or erlotinib combined with chemotherapy had longer PFS compared with chemotherapy alone (HR: 0.54; 95% CI: 0.30-0.95, P ¼ 0.04) [46] . However, there was no difference in OS. A phase II study of pemetrexed plus gefitinib versus gefitinib alone showed that combined treatment was better in terms of PFS (adjusted HR: 0.68; 95% CI: 0.48-0.96, two-sided P ¼ 0.029), again without a difference in OS [47] . EGFR TKIs were combined with targeted agents in several randomised studies. Most of these studies did not show any difference in PFS or OS. In a phase II randomised study in Japan, erlotinib combined with bevacizumab versus erlotinib alone showed a better PFS in the combination arm when compared with erlotinib alone (median 16.0 versus 9.7 months, respectively, HR: 0.54; 95% CI: 0.46-0.79, P ¼ 0.0015) [48] . Several phase II and III studies are on-going to confirm this early efficacy observation.
Other treatment options for EGFR-mutant tumours Chemotherapy as front-line treatment
Chemotherapy is not recommended as front-line treatment of patients with actionable EGFR mutations. However, for patients with EGFR exon 20 insertion or patients with EGFR mutations which have previously reported to be insensitive to EGFR TKI treatment, chemotherapy should be given as first-line treatment [49] .
Immunotherapy as front-line treatment
Tumours with EGFR mutations in general do not respond well to anti-PD-1 or anti-PD-L1 checkpoint inhibitors. A meta-analysis of patients in three second-line studies comparing nivolumab, pembrolizumab, or atezolizumab to docetaxel showed that in contrast to better OS using immunotherapy versus docetaxel in patients with EGFRwt tumours, there was no OS benefit using immunotherapy in those with EGFR-mutant tumours [50] . Limited patients with EGFR-mutant tumours were treated with nivolumab or nivolumab plus ipilimumab as first-line treatment. The number of patients was too low to make any conclusions. In fact, the landmark KEYNOTE-024 study has intentionally excluded patients with EGFR mutations, thus the data from this successful randomised study on first-line pembrolizumab are not applicable to this population. Currently, the use immunotherapy is not recommended for EGFR-mutant patients as first-or second-line treatment outside of clinical trials.
Discussion

Conclusion
Improvements in our knowledge of the genomic landscape of NSCLC coupled with the development of a targeted drug approach in this disease has resulted in major changes in our treatment algorithm. Newly diagnosed advanced stage NSCLC patients should now be molecularly characterised at diagnosis. While the presence of EGFR activating mutations does not guarantee positive treatment outcomes with EGFR-TKIs, prior landmark clinical trials, and clinical experience has shown that a large majority of patients with EGFR sensitising mutations do indeed respond favourably to first-and second-generation EGFR TKIs when used in the frontline setting. Identification of specific non-sensitising EGFR mutations is also of profound importance, serving to triage these patients away from EGFR TKIs, which presently are considered ineffective treatments in this population group.
Significant advances have been made in recent years with the development of third-generation EGFR-TKIs, such as osimertinib. This will be discussed in the next chapters of this edition.
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